Elmasri Saleem 4

What Happened

• Saleem Elmasri, Chief Financial Officer of Jupiter Neurosciences (JUNS), reported a grant of 525,565 derivative securities (stock options) on 2026-06-02. The Form 4 lists an acquisition price of $0.00 (award/grant), so no cash changed hands in the filing. This was an equity compensation award, not a purchase or sale of shares.

Key Details

• Transaction date: 2026-06-02; Form 4 filed 2026-06-04 (filed within the normal 2-business-day window).
• Reported amount: 525,565 options; reported acquisition price: $0.00.
• Shares owned after the transaction: not specified in the filing.
• Footnote details: 325,565 options granted as a discretionary bonus for services during fiscal 2025; 200,000 options granted as long-term incentive compensation under the 2025 Equity Incentive Plan. Options vest over three years beginning September 2, 2026, in equal quarterly installments, subject to continued employment.
• Transaction code: A (award/grant). No 10b5-1 plan, tax-withholding, or late-filing flags noted.

Context

• These are option awards (derivative securities) — the filing reflects a grant, not an exercise or sale. The options will vest in the future per the schedule above; they do not represent immediately tradable shares unless and until they are exercised and any post-exercise restrictions lapse.
• Equity grants are common executive compensation; they are informative about pay and potential future dilution but do not, by themselves, indicate buying or selling sentiment.